Is EYES or QYLD a better dividend investment in 2026?

EYES currently yields 48.31% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: EYES offers higher current income.

What is the dividend yield difference between EYES and QYLD?

EYES has a forward dividend yield of 48.31% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 36.39 percentage points.

Home › Compare › EYES vs QYLD

EYES vs QYLD: Dividend Comparison 2026

EYES yields 48.31% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EYES wins by $335.5K in total portfolio value

INVESTMENT

TIME HORIZON10 years

EYES

● Live price

48.31%

Share price

$4.14

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$360.9K

Annual income

$71,162.95

Full EYES calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — EYES vs QYLD

📍 EYES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EYES	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EYES + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EYES pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EYES

Annual income on $10K today (after 15% tax)

$4,106.28/yr

After 10yr DRIP, annual income (after tax)

$60,488.51/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, EYES beats the other by $55,678.09/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EYES + QYLD for your $10,000?

EYES: 50%QYLD: 50%

100% QYLD50/50100% EYES

Portfolio after 10yr

$193.2K

Annual income

$38,411.13/yr

Blended yield

19.88%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EYES right now

EYES

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-1.9

Piotroski

3/9

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EYES buys

QYLD buys

No recent congressional trades found for EYES or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEYESQYLD

Forward yield	48.31% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$360.9K ✓	$25.4K
Annual income after 10y	$71,162.95 ✓	$5,659.31
Total dividends collected	$285.6K ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: EYES vs QYLD ($10,000, DRIP)

Year	EYES Portfolio	EYES Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$15,531	$4,830.92	$10,352	$1,192.36	+$5.2K → EYES
2	$23,630	$7,012.02	$10,830	$1,347.57	+$12.8K → EYES
3	$35,255	$9,970.75	$11,460	$1,539.07	+$23.8K → EYES
4	$51,625	$13,902.68	$12,275	$1,777.84	+$39.4K → EYES
5	$74,266	$19,026.49	$13,323	$2,078.95	+$60.9K → EYES
6	$105,044	$25,579.93	$14,667	$2,463.34	+$90.4K → EYES
7	$146,212	$33,814.22	$16,396	$2,960.57	+$129.8K → EYES
8	$200,433	$43,987.07	$18,631	$3,612.97	+$181.8K → EYES
9	$270,818	$56,354.64	$21,548	$4,482.15	+$249.3K → EYES
10	$360,939	$71,162.95	$25,398	$5,659.31	+$335.5K → EYES

EYES vs QYLD: Complete Analysis 2026

EYES — Stock

As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Full EYES Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this EYES vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EYES vs SCHD EYES vs JEPI EYES vs O EYES vs KO EYES vs MAIN EYES vs XYLD EYES vs JEPQ EYES vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.